1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Renal Cell Carcinoma Pipeline Analysis Report for 2017

Renal Cell Carcinoma Pipeline Analysis Report for 2017

  • December 2017
  • 25 pages
  • ID: 5251485
  • Format: PDF
  • By EffeMarket

Summary

Table of Contents

Search Inside

Renal cell carcinoma (RCC), also known as kidney cancer or renal adenocarcinoma, is the most common type of kidney cancer in adults, occurring at an average age of 64 years. It is a disease which develops in the lining of the kidney tubules and grows into a mass or tumor.

It accounts for approximately 3% of adult malignancies and 90% to 95% of malignant neoplasm (cancer cells) involving the kidneys. Its signs and symptoms include weight loss, fever, hypertension, malaise, night sweats, and blood in the urine.
Renal cell carcinoma is the ninth leading cause of cancer death in the US. The 5-year survival rates initially reported by Robson in 1969 were 66 percent for stage I renal carcinoma, 64 percent for stage II, 42 percent for stage III, and only 11 percent for stage IV.

The age-adjusted incidence of renal cell carcinoma has been rising by 3 percent per year. In general men are twice as prone to RCC as women. It represents about four percent of all cancer diagnoses and every year, more than 337,000 people are diagnosed with kidney cancer.

Annually 143,000 deaths are caused by kidney cancers. According to the National Cancer Institute, in 2017, RCC is estimated to be diagnosed in approximately 63,990 people in the US. In US alone, almost 14,000 deaths occur from RCC each year. In 2012, there were approximately 84,000 cases of RCC and 35,000 deaths due to kidney cancer in 2012 in the European Union.

The targeted therapies are usually the first line treatment option to treat in-operable or metastatic kidney cancer. Currently, these are usually given as monotherapy. But now, clinical trials are in progress to check if combination therapy (with standard therapy, other approved drugs or new molecules) is better than monotherapy.

Renal Cell Carcinoma Pipeline Analysis Report: 2017 includes list of pipeline of drugs in clinical development, and pipeline analysis by phase, indication sub-type, molecule type and company. The report provides the detailed analysis of the key five promising drugs in clinical development which are Savolitinib, AGS-003, Atezolizumab, Tivozanib and Avelumab. Many big pharma companies are working in developing drugs for the treatment of renal cell carcinoma.

The companies are majorly focused on developing treatment for the advanced/metastatic form of kidney cancer. Bristol-Myers Squibb in collaboration with Ono Pharmaceutical is leading in this space.

Other leading companies working in this area are Novartis, Roche, Eisai, Merck & Co. (as Merck Sharp & Dohme), AstraZeneca, Pfizer and, Takeda. Very few companies like Bristol-Myers Squibb, Novartis, Eisai and Roche are investing on the rare variant, the non-clear cell RCC.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Peripheral T-Cell Lymphomas (PTCL) Global Clinical Trials Review, H2, 2019

Peripheral T-Cell Lymphomas (PTCL) Global Clinical Trials Review, H2, 2019

  • $ 2500
  • December 2019

Peripheral T-Cell Lymphomas (PTCL) Global Clinical Trials Review, H2, 2019Summaryclinical trial report, “Peripheral T-Cell Lymphomas (PTCL) Global Clinical Trials Review, H2, 2019" provides an overview ...

Hypereosinophilic Syndrome - Pipeline Review, H2 2019

Hypereosinophilic Syndrome - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Hypereosinophilic Syndrome - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Hypereosinophilic Syndrome - Pipeline Review, H2 2019, provides an overview of ...

Lupus Nephritis Global Clinical Trials Review, H2, 2019

Lupus Nephritis Global Clinical Trials Review, H2, 2019

  • $ 2500
  • December 2019

Lupus Nephritis Global Clinical Trials Review, H2, 2019Summaryclinical trial report, “Lupus Nephritis Global Clinical Trials Review, H2, 2019" provides an overview of Lupus Nephritis clinical trials ...


ref:plp2017

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on